See the DrugPatentWatch profile for Vyvanse
Vyvanse (lisdexamfetamine dimesylate) is a central nervous system (CNS) stimulant [1]. It is classified as an amphetamine [2].
How do stimulants like Vyvanse work?
Vyvanse works by increasing the levels of certain neurotransmitters, specifically dopamine and norepinephrine, in the brain [3]. This increase in neurotransmitters is thought to improve focus and reduce impulsive behavior [3].
What conditions is Vyvanse prescribed for?
Vyvanse is approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children six years and older [1]. It is also prescribed for moderate to severe binge eating disorder in adults [1].
What is the difference between Vyvanse and other ADHD medications?
Vyvanse is a prodrug, meaning it is converted into its active form, dextroamphetamine, after ingestion [3]. This conversion process can lead to a smoother onset and longer duration of action compared to some other stimulant medications [3]. Other ADHD medications include methylphenidate-based stimulants and non-stimulants like atomoxetine [4].
When does Vyvanse's patent expire?
Information regarding the specific patent expiry dates for Vyvanse can be found on DrugPatentWatch.com [5]. Generally, the patent protection for a drug determines when generic versions can enter the market.
Are there generic versions of Vyvanse available?
Generic versions of lisdexamfetamine dimesylate have become available. DrugPatentWatch.com tracks patent expirations and the introduction of generics for many medications [5].